SCHEMBL15765005

SCHEMBL15765005

CCOC(=O)/C=C/c1nccn1CC

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
TTR P02766 1/20 0.41
DPP4 P27487 1/20 0.41
MAPT P10636 2/20 0.40
LMNA P02545 1/20 0.40
HTT P42858 1/20 0.40
CYP3A4 P08684 1/20 0.40
FDPS P14324 1/20 0.39
MLYCD O95822 1/20 0.39
HCAR2 Q8TDS4 1/20 0.39
MAOB P27338 1/20 0.38
LPO P22079 2/20 0.38
CCNC P24863 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18084012 0.87 KMT2A (0.41) CA12CA1CA2CA7CA9
SCHEMBL18106169 0.85 FDPS (0.41) CA12CA1CA2CA7CA9
SCHEMBL6182379 0.84 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL6376840 0.84 CA12 (0.45) CA12CA1CA2CA7CA9
SCHEMBL20558910 0.83 OPRD1 (0.48) CA12CA1CA2CA7CA9
SCHEMBL15758042 0.81 SMN1; SMN2 (0.39) LMNACYP3A4KDM4E
SCHEMBL15758840 0.81 SMN1; SMN2 (0.39) LMNACYP3A4KDM4E
SCHEMBL23723019 0.80 CA12 (0.42) CA12CA1CA2CA7CA9
SCHEMBL17897627 0.79 NPC1 (0.35) CA12CA1CA2CA7CA9
SCHEMBL19937735 0.79 SMN1; SMN2 (0.34) MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-9938258-B2 Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof Karyopharm Therapeutics Inc. (US) 2018-04-10 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof Karyopharm Therapeutics Inc. 2016-08-04 US disclosed
WO-2014085607-A1 SUBSTITUTED 2,3-DIHYDROBENZOFURANYL COMPOUNDS AND USES THEREOF Karyopharm Therapeutics Inc. (US) 2014-06-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221994-A1 Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses Thereof BCL6, MALT1, BCL3 CA12 918/4885CA1 3207/4885CA2 2044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.